Brief: Galectin Therapeutics Reports 2022 Net Loss Of $0.65 Per Share

Galectin Therapeutics

30/03/2023 13:55

March 30 (Reuters) - Galectin Therapeutics Inc  GALT.O :
    * GALECTIN THERAPEUTICS INC - FOR THE YEAR ENDED DECEMBER
31,
2022, REPORTED A NET LOSS APPLICABLE TO COMMON STOCKHOLDERS OF
$0.65 PER SHARE
    * GALECTIN THERAPEUTICS INC -  EXPECTS WILL REQUIRE MORE
CASH TO
FUND OPERATIONS AFTER DECEMBER 31, 2024
    * GALECTIN THERAPEUTICS INC -  AS OF DECEMBER 31, 2022, HAD
$18.6
MILLION OF CASH AND CASH EQUIVALENTS
    * GALECTIN THERAPEUTICS - CO BELIEVES IT WILL BE ABLE TO
OBTAIN
ADDITIONAL FINANCING AS NEEDED
    * GALECTIN THERAPEUTICS-BELIEVES HAS SUFFICIENT CASH TO FUND
CURRENTLY PLANNED OPERATIONS & RESEARCH & DEVELOPMENT ACTIVITIES
THROUGH AT LEAST DEC 31, 2024

Source text for Eikon:  ID: 
Further company coverage:  GALT.O 

 ((Reuters.Briefs@thomsonreuters.com;))